SOLV · 8-K · 20260805PR000045
Revenue Performance and Mix
Solventum Corp · 2026-08-05 · Importance 54 · Surprise 40 · No source text
Second-quarter 2026 sales were $2.209 billion, up 2.2% year over year on a reported basis and 9.5% organically. MedSurg sales increased 12.7% to $1.372 billion, including Advanced Wound Care sales of $537 million, up 14.9%, and Infection Prevention and Surgical Solutions sales of $836 million, up 11.3%. Dental Solutions sales rose 17.0% to $396 million, while Health Information Systems sales increased 4.4% to $354 million. Organic growth primarily reflected volume and product mix, including advance orders ahead of ERP cutovers, while divestitures reduced reported growth by 8.3 percentage points.
Key facts
- Reported sales for Q2 2026: $2.2 billion (Net sales $2,209 million), increased 2.2% on a reported basis source
- Net sales for the six months ended June 30, 2026: $4,216 million (decreased 0.4% year-over-year) source
- Organic sales growth in Q2 2026: 9.5% source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +2.2% | Reported sales for Q2 2026: $2.2 billion (Net sales $2,209 million), increased 2.2% on a reported basis |
| revenue | negative | realized | -0.8% | Net sales for the six months ended June 30, 2026: $4,216 million (decreased 0.4% year-over-year) |